How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
It isn’t yet possible to diagnose chronic traumatic encephalopathy—more widely known as CTE—in the living. Yet for many people, especially athletes, the fear is real. In fact, 1 in 3 former NFL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback